Harshil Dhruv

Renaissance Life Therapies — United Kingdom

Medicine · Health Sciences

21h-index5.2kcitations239works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(106), Radiopharmaceutical Chemistry and Applications(37), Cancer, Hypoxia, and Metabolism(28), Cancer Mechanisms and Therapy(25), Cancer Genomics and Diagnostics(23)

Publications239 total

Discovery of a Novel Series of <i>iso</i>-Indolinone-Based Glutarimides as Highly Efficacious and Selective IKZF2 Molecular Glue Degraders
Journal of Medicinal Chemistry·2025
Overcoming CK1α liability in the discovery of a series of isoIndolinone Glutarimides as selective IKZF2 molecular glue degraders
Bioorganic & Medicinal Chemistry Letters·2025· 1 cited
Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy
Nature Communications·2025· 9 citedOpen Access
Abstract LB237: p300-selective degraders illustrate potent anti-tumor activity in a distinct subset of cancers
Cancer Research·2025
Overcoming Ck1a Liability in the Discovery of a Series of Iso-Indolinone Glutarimides as Selective Ikzf2 Molecular Glue Degraders
SSRN Electronic Journal·2025Open Access
Supplementary Figure S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
2024Open Access
Supplementary Figure S6 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
2024Open Access
Supplementary Table S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
2024Open Access
Supplementary Appendix S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
2024Open Access
Supplementary Table S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
2024Open Access
Supplementary Figure S7 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
2024Open Access
Supplementary Table S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
2024Open Access
Data from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
2024Open Access
Supplementary Figure S3 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
2024Open Access
Supplementary Figure S5 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
2024Open Access
Supplementary Figure S1 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
2024Open Access
Supplementary Figure S6 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
2024Open Access
Supplementary Figure S7 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
2024Open Access
Supplementary Figure S2 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
2024Open Access
Supplementary Figure S4 from Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for Patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT
2024Open Access
page 1 of 12Next →

Frequent Co-authors

Michael E. Berens(34), Nhan L. Tran(18), Sen Peng(12), Joseph C. Loftus(10), Seungchan Kim(8), Serdar Tuncali(6), Alison Roos(5), Jean Kloss(5), Nanyun Tang(5), Patricia LoRusso(4), Nader Sanai(4), Jenny Eschbacher(4), Landon J. Inge(4), Jeffrey A. Winkles(4), Patrick Pirrotte(4), Jeffrey Kiefer(4), Manmeet S. Ahluwalia(4), Stuart L. Schreiber(3), Andrea Califano(3), Jann N. Sarkaria(3)